| Name | Title | Contact Details |
|---|---|---|
William Teeple |
Sr. Director of Information Technology | Profile |
James Metzger |
Director of Cybersecurity and Information Security | Profile |
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.
Affiliated Sante Group is a Silver Spring, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Spire’s Remote Patient Monitoring service pairs revolutionary respiratory sensing technology with licensed medical staff to identify changes in patient health and intervene earlier.
WIL Research Company, Inc. is a privately held global Contract Research Organization that provides product safety toxicological research, bioanalytical, and formulation services to the pharmaceutical, biotechnology, chemical, agrochemical, and food products industries as well as manufacturing support for clinical trials.
Medical Billing Practice Management is a Las Cruces, NM-based company in the Healthcare, Pharmaceuticals, and Biotech sector.